**Suppl 1.** Correlation of Systems Involved with Clinical Features

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Clinical feature | Neuropsychiatric (n = 33) | Endocrine (n = 9) | Musculoskeletal (n = 16) | Renal (n = 18) | Cardiovascular (n = 13) | Peripheral vascular (n = 10) |
| Gender, n (%) |  |  |  |  |  |  |
| Male | 6/7 (85.7%) | 1/7 (14.3%) | 0 | 3/7 (42.9%) | 1/7 (14.3%) | 2/7 (28.6%) |
| Female | 27/69 (39.1%) | 8/69 (11.6%) | 16/69 (23.2%) | 15/69 (21.7%) | 12/69 (17.4%) | 8/69 (11.6%) |
| P-value | 0.018 | 0.834 | 0.153 | < 0.001 | 0.835 | 0.20 |
| Age (mean ± SD) |  |  |  |  |  |  |
| Yes | 37.1 ± 10.9 | 52.3 ± 6.6 | 38.2 ± 7.5 | 41.6 ± 12.1 | 35.9 ± 10.8 | 38.9 ± 10.3 |
| No | 40.4 ± 10.6 | 37.1 ± 9.9 | 39.1 ± 11.5 | 38.1 ± 10.3 | 39.6 ± 10.7 | 38.9 ± 10.9 |
| P-value | 0.192 | 0.001 | 0.757 | 0.229 | 0.258 | 0.991 |
| Age at diagnosis (mean ± SD) |  |  |  |  |  |  |
| Yes | 26.5 ± 10.9 | 40.7 ± 9.2 | 26.9 ± 7.2 | 31.4 ± 3.0 | 25.9 ± 9.7 | 28.1 ± 10.9 |
| No | 30.3 ± 9.9 | 27.0 ± 9.6 | 29.1 ± 11.2 | 27.8 ± 9.6 | 29.2 ± 10.6 | 28.7 ± 10.5 |
| P-value | 0.116 | 0.001 | 0.450 | 0.196 | 0.306 | 0.861 |
| BMI, n (%) |  |  |  |  |  |  |
| Underweight | 5 (15.2%) | 0 | 1 (6.3%) | 0 | 2 (15.4%) | 0 |
| Normal | 12 (36.4%) | 2 (22.2%) | 4 (25.0%) | 8 (44.4%) | 4 (30.8%) | 2 (20.0%) |
| Overweight | 6 (18.2%) | 0 | 2 (12.5%) | 2 (11.1%) | 2 (15.4%) | 4 (40.0%) |
| Obese | 5 (15.2%) | 4 (44.4%) | 5 (31.3%) | 6 (11.1%) | 3 (23.1%) | 2 (20.0%) |
| Morbid | 5 (15.2%) | 3 (33.3%) | 4 (25.0%) | 2 (11.1%) | 2 (15.4%) | 2 (20.0%) |
| P-value | 0.330 | 0.153 | 0.704 | 0.199 | 0.960 | - |
| SDI, n (%) |  |  |  |  |  |  |
| Positive | 33/76 (43.4%) | 9/76 (11.8%) | 16/76 (21.1%) | 18/76 (23.7%) | 13/76 (17.1%) | 10/76 (13.2%) |
| Negative | 43/76 (56.6%) | 67/76 (88.2%) | 60/76 (78.9%) | 58/76 (76.3%) | 63/76 (82.9%) | 66/76 (86.8%) |
| P-value | 0.105 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Medication, n (%) |  |  |  |  |  |  |
| Corticosteroid |  |  |  |  |  |  |
| Yes | 17/33 (51.5%) | 5/9 (55.6%) | 11/16 (68.8%) | 17/18 (94.4%) | 7/13 (53.8%) | 2/10 (20.0%) |
| No | 16/33 (48.5%) | 4/9 (44.4%) | 5/16 (31.3%) | 1/18 (5.6%) | 6/13 (46.2%) | 8/10 (80.0%) |
| P-value | 0.803 | 0.638 | 0.034 | 0.001 | 0.697 | 0.007 |
| Hydroxychloroquine |  |  |  |  |  |  |
| Yes | 29/33 (87.9%) | 8/9 (88.9%) | 14/16 (87.5%) | 15/18 (83.3%) | 11/13 (84.6%) | 6/10 (60.0%) |
| No | 4/33 (12.1%) | 1/9 (11.1%) | 2/16 (12.5%) | 3/18 (16.7%) | 2/13 (15.4%) | 4/10 (40.0%) |
| P-value | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 | 0.001 |
| Mycophenolate mofetil |  |  |  |  |  |  |
| Yes | 15/33 (45.5%) | 5/9 (55.6%) | 7/16 (43.8%) | 14/18 (77.8%) | 8/13 (61.5%) | 6/10 (60.0%) |
| No | 18/33 (54.5%) | 4/9 (44.4%) | 9/16 (56.3%) | 4/18 (22.2%) | 5/13 (38.5%) | 4/10 (40.0%) |
| P-value | 0.459 | 0.638 | 0.478 | 0.006 | 0.238 | 0.073 |
| Azithromycin |  |  |  |  |  |  |
| Yes | 13/33 (39.4%) | 3/9 (33.3%) | 6/16 (37.5%) | 15/18 (83.3%) | 3/13 (23.1%) | 3/10 (30.0%) |
| No | 20/33 (60.6%) | 6/9 (66.7%) | 10/16 (62.5%) | 3/18 (16.7%) | 10/13 (76.9%) | 7/10 (70.0%) |
| P-value | 0.085 | 0.158 | 0.159 | 0.001 | 0.006 | 0.37 |
| Lupus, n (%) |  |  |  |  |  |  |
| Yes | 12/33 (36.4%) | 6/9 (66.7%) | 6/16 (37.5%) | 15/18 (83.3%) | 8/13 (61.5%) | 3/10 (30.0%) |
| No | 21/33 (63.6%) | 3/9 (33.3%) | 10/16 (62.5%) | 3/18 (16.7%) | 5/13 (38.5%) | 7/10 (70.0%) |
| P-value | 0.026 | 0.159 | 0.159 | < 0.001 | 0.238 | 0.073 |
| SLEDAI-2k, n (%) |  |  |  |  |  |  |
| Negative | 19/33 (57.6%) | 6/9 (66.7%) | 9/16 (56.3%) | 9/18 (50.0%) | 8/13 (61.5%) | 5/10 (50.0%) |
| Positive | 14/33 (42.4%) | 3/9 (33.3%) | 7/16 (43.8%) | 9/18 (50.0%) | 5/13 (38.5%) | 5/10 (50.0%) |
| P-value | 0.218 | 0.159 | 0.478 | 1.00 | 0.238 | 1.0 |